A Study of Eritoran (E5564) Administered IV Over 14 Days Prior to and During Bone Marrow Engraftment in BMT Patients Who Have Received Myeloablative Conditioning Treatment and Are Receiving Bone Marrow or Stem Cells From Matched Related Donors

Sponsor

Eisai Inc. (Industry)

Overall Status

Terminated

CT.gov ID

NCT00756912

Collaborator

(none)

Enrollment

Location

Arm

Study Details

Study Description

Brief Summary

This is a study designed to assess the safety of administration of up to 3 dose levels of eritoran in subjects undergoing or scheduled to undergo allogeneic bone marrow transplant (BMT). An allogeneic BMT is the transplantation of blood stem cells taken from the bone marrow or blood of another person.

Condition or Disease	Intervention/Treatment	Phase
Leukemia	Drug: E5564	Phase 1

Detailed Description

Please note: in the original protocol, the study phase is listed as "Phase Ib", although the Official Title reads "Phase I".

Study Design

Study Type:

Interventional

Actual Enrollment :

30 participants

Allocation:

Non-Randomized

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Prevention

Official Title:

A Phase I, Open-Label, Dose Escalation Study of Eritoran (E5564) Administered IV Over 14 Days Prior to and During Bone Marrow Engraftment in BMT Patients Who Have Received Myeloablative Conditioning Treatment and Are Receiving Bone Marrow or Stem Cells From Matched Related Donors

Study Start Date :

Sep 1, 2008

Actual Primary Completion Date :

Nov 1, 2008

Arms and Interventions

Arm	Intervention/Treatment
Experimental: 1	Drug: E5564 Three dose levels of Eritoran IV over 14 days for a total of 32, 96, and 224 mg over 14 days. Other Names: Eritoran

Arm

Intervention/Treatment

Experimental: 1

Drug: E5564

Three dose levels of Eritoran IV over 14 days for a total of 32, 96, and 224 mg over 14 days.

Other Names:

Eritoran

Outcome Measures

Primary Outcome Measures

Safety and assessments will be done daily. [Performed daily through Day 28, with follow-up every other week to Day 100 and at 1 year post-transplant.]

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 55 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Subjects must meet all of the inclusion criteria outlined below in order to be eligible to participate in this study:

Adult subjects (aged 18 to 55 years old) undergoing or scheduled to undergo myeloablative conditioning and allogeneic BMT, or stem cells from matched donors.
Subjects using either busulfan or total body irradiation (TBI) containing regimens for

BMT for the treatment of malignant and nonmalignant diseases. For example:

Cyclophosphamide and Total Body Irradiation (CY-TBI) with a TBI dose of at least 1200 cGy of fractionated TBI
Etoposide and Total Body Irradiation (VP16-TBI) with a TBI dose of at least 1200 cGy of fractionated TBI
Busulfan and cyclophosphamide (BU-CY) with at least 14 mg/kg busulfan orally or 11.2 mg/kg busulfan intravenously (14 x 0.8 correction factor) or a targeted busulfan dosing strategy aimed at a serum concentration greater than 600 ng/mL at steady state.

Leukemia patients with:

acute myelogenous leukemia (AML)
acute lymphoblastic leukemia (ALL) in first or subsequent complete remission
chronic myelogenous leukemia (CML) in first or subsequent chronic phase or in accelerated phase
myelodysplastic syndrome (MDS) patients.

Subjects with non-Hodgkin's lymphoma who are in complete remission as determined by physical exam, CT and PET scans, and are otherwise considered candidates for allogeneic BMT as judged by the treating institution

Available matched related CD34+ stem cells (target cell dose between 2 x 10^{6/kg and
10 x 10}6/kg (actual body weight)) for transplantation (matched at 6/6 HLA at Class I HLA-A and B and Class II HLA-DRBI).
Sex distribution: men or nonpregnant women. Women of childbearing potential must have a negative serum β-human chorionic gonadotropin (hCG) or urine assay prior to eritoran treatment or prior to the beginning of conditioning treatment. Menopausal women must have been amenorrheic for at least 12 months.
Race: any.
Has signed informed consent before any study-specific procedures are performed.

Exclusion Criteria:

Unwilling or unable to agree to be fully evaluated for all follow-up visits. The subject or subject's representative and the study staff should agree to perform all study assessments even if the subject is discharged from the hospital.
Seropositive for human immunodeficiency virus (HIV); testing is not needed if already performed (documentation required) as part of screening for conditioning treatment.
Subjects with a documented or possible systemic infection, or suspected of having a medically significant viral, bacterial, or fungal infection at the beginning of treatment on Day -3.
Have taken any investigational medications (ie, not approved by the FDA for any indication) within the 30-day period prior to enrollment into the study.
Karnofsky Performance Status (KPS) <60%.
Have previously received a bone marrow or stem cell transplant.
Are to receive T-cell depleted BMT or stem cell infusions.
Are pregnant or lactating.
Known sensitivity to eritoran or its excipients.
Prior malignancies treated with a curative intent of < 5 years will not be allowed. Previously treated cancer with a curative intent of > 5 years will be allowed.
Legal incapacity.
Any of the following laboratory parameters within 2 days prior to the beginning of treatment on Day -3:

direct bilirubin ≥ 2x ULN
liver function tests (ALT or AST) with values ≥ 3x ULN
serum creatinine ≥ 2x ULN

Subjects who are enrolled in other interventional, investigational protocols. As aGvHD is likely to only occur after treatment with eritoran is completed, investigational treatments for Grades III and IV aGvHD may be allowed and should be discussed with the Sponsor.
Subjects with a history of or with current pulmonary disease with forced vital capacity (FVC) or forced expiratory volume in 1 second (FEV1) < 60% predicted (corrected for hemoglobin).
Subjects with a history of a cardiac ejection fraction < 45%, or with marked screening or baseline prolongation QT/QTc interval (QTc interval > 470 mSec).